Kymera Begin Period Cash Flow vs Net Borrowings Analysis

KYMR Stock

USD 32.11 0.05 0.16%

Kymera Therapeutics financial indicator trend analysis is infinitely more than just investigating Kymera Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kymera Therapeutics is a good investment. Please check the relationship between Kymera Therapeutics Begin Period Cash Flow and its Net Borrowings accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.

Begin Period Cash Flow vs Net Borrowings

Begin Period Cash Flow vs Net Borrowings Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kymera Therapeutics Begin Period Cash Flow account and Net Borrowings. At this time, the significance of the direction appears to have pay attention.

The correlation between Kymera Therapeutics' Begin Period Cash Flow and Net Borrowings is -0.78. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Net Borrowings in the same time period over historical financial statements of Kymera Therapeutics, assuming nothing else is changed. The correlation between historical values of Kymera Therapeutics' Begin Period Cash Flow and Net Borrowings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Kymera Therapeutics are associated (or correlated) with its Net Borrowings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Borrowings has no effect on the direction of Begin Period Cash Flow i.e., Kymera Therapeutics' Begin Period Cash Flow and Net Borrowings go up and down completely randomly.

Correlation Coefficient

-0.78

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Net Borrowings

The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.

Most indicators from Kymera Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kymera Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.As of 06/02/2024, Sales General And Administrative To Revenue is likely to grow to 1.19, while Selling General Administrative is likely to drop slightly above 30.3 M.

	2021	2022	2023	2024 (projected)
Interest Expense	175K	176K	196K	132.7K
Depreciation And Amortization	488K	6.6M	3.6M	2.5M

Interest Expense Depreciation And Amortization

Kymera Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.66	-0.05	0.94	0.99	0.81	0.95	0.57	0.79	0.5	-0.84	0.88	0.54	0.74	-0.57	0.89	0.98	0.55	0.78	-0.2	0.66	0.97	0.83	0.72	0.99	0.67
Short Long Term Debt Total	0.66		0.52	0.64	0.6	0.54	0.8	0.99	0.38	0.47	-0.91	0.86	0.8	0.84	0.06	0.84	0.55	0.97	0.72	0.13	1.0	0.73	0.79	0.69	0.6	1.0
Other Current Liab	-0.05	0.52		-0.21	-0.04	-0.4	0.18	0.6	-0.54	-0.26	-0.43	0.19	0.61	-0.01	0.12	0.4	-0.17	0.6	0.44	0.01	0.52	0.12	0.47	-0.11	-0.04	0.54
Total Current Liabilities	0.94	0.64	-0.21		0.89	0.94	0.87	0.55	0.91	0.65	-0.72	0.85	0.43	0.82	-0.38	0.76	0.93	0.5	0.65	-0.02	0.64	0.88	0.65	0.86	0.89	0.64
Total Stockholder Equity	0.99	0.6	-0.04	0.89		0.72	0.95	0.52	0.74	0.46	-0.83	0.83	0.49	0.66	-0.65	0.88	0.98	0.51	0.76	-0.35	0.6	0.97	0.85	0.59	1.0	0.62
Other Liab	0.81	0.54	-0.4	0.94	0.72		0.7	0.44	0.96	0.64	-0.56	0.74	0.29	0.83	-0.2	0.56	0.82	0.38	0.47	0.18	0.54	0.69	0.42	0.91	0.72	0.52
Net Tangible Assets	0.95	0.8	0.18	0.87	0.95	0.7		0.74	0.68	0.53	-0.94	0.89	0.6	0.79	-0.46	0.96	0.92	0.74	0.79	-0.28	0.8	0.96	0.93	0.64	0.95	0.82
Property Plant And Equipment Net	0.57	0.99	0.6	0.55	0.52	0.44	0.74		0.28	0.43	-0.88	0.8	0.79	0.79	0.14	0.8	0.46	0.99	0.68	0.14	0.99	0.66	0.76	0.62	0.52	0.99
Current Deferred Revenue	0.79	0.38	-0.54	0.91	0.74	0.96	0.68	0.28		0.69	-0.46	0.61	0.07	0.74	-0.31	0.5	0.84	0.25	0.34	-0.06	0.38	0.65	0.38	0.76	0.74	0.37
Net Debt	0.5	0.47	-0.26	0.65	0.46	0.64	0.53	0.43	0.69		-0.38	0.51	0.0	0.78	0.23	0.32	0.47	0.47	0.01	-0.18	0.47	0.45	0.27	0.49	0.46	0.46
Retained Earnings	-0.84	-0.91	-0.43	-0.72	-0.83	-0.56	-0.94	-0.88	-0.46	-0.38		-0.9	-0.79	-0.77	0.32	-0.97	-0.76	-0.88	-0.85	0.13	-0.91	-0.91	-0.95	-0.61	-0.83	-0.93
Accounts Payable	0.88	0.86	0.19	0.85	0.83	0.74	0.89	0.8	0.61	0.51	-0.9		0.8	0.85	-0.22	0.86	0.79	0.78	0.82	0.11	0.86	0.93	0.79	0.81	0.83	0.86
Cash	0.54	0.8	0.61	0.43	0.49	0.29	0.6	0.79	0.07	0.0	-0.79	0.8		0.5	-0.11	0.74	0.4	0.75	0.87	0.34	0.8	0.67	0.69	0.57	0.49	0.8
Non Current Assets Total	0.74	0.84	-0.01	0.82	0.66	0.83	0.79	0.79	0.74	0.78	-0.77	0.85	0.5		0.11	0.68	0.68	0.78	0.47	0.12	0.84	0.72	0.58	0.82	0.66	0.82
Non Currrent Assets Other	-0.57	0.06	0.12	-0.38	-0.65	-0.2	-0.46	0.14	-0.31	0.23	0.32	-0.22	-0.11	0.11		-0.48	-0.65	0.15	-0.54	0.5	0.06	-0.54	-0.52	-0.04	-0.65	0.02
Other Assets	0.89	0.84	0.4	0.76	0.88	0.56	0.96	0.8	0.5	0.32	-0.97	0.86	0.74	0.68	-0.48		0.83	0.78	0.9	-0.2	0.84	0.93	0.98	0.6	0.88	0.86
Cash And Short Term Investments	0.98	0.55	-0.17	0.93	0.98	0.82	0.92	0.46	0.84	0.47	-0.76	0.79	0.4	0.68	-0.65	0.83		0.43	0.72	-0.27	0.55	0.93	0.78	0.68	0.98	0.57
Net Receivables	0.55	0.97	0.6	0.5	0.51	0.38	0.74	0.99	0.25	0.47	-0.88	0.78	0.75	0.78	0.15	0.78	0.43		0.61	0.04	0.97	0.64	0.76	0.53	0.51	0.98
Common Stock Shares Outstanding	0.78	0.72	0.44	0.65	0.76	0.47	0.79	0.68	0.34	0.01	-0.85	0.82	0.87	0.47	-0.54	0.9	0.72	0.61		0.07	0.72	0.84	0.85	0.62	0.76	0.73
Non Current Liabilities Total	-0.2	0.13	0.01	-0.02	-0.35	0.18	-0.28	0.14	-0.06	-0.18	0.13	0.11	0.34	0.12	0.5	-0.2	-0.27	0.04	0.07		0.13	-0.21	-0.36	0.48	-0.35	0.08
Capital Lease Obligations	0.66	1.0	0.52	0.64	0.6	0.54	0.8	0.99	0.38	0.47	-0.91	0.86	0.8	0.84	0.06	0.84	0.55	0.97	0.72	0.13		0.73	0.79	0.69	0.6	1.0
Other Current Assets	0.97	0.73	0.12	0.88	0.97	0.69	0.96	0.66	0.65	0.45	-0.91	0.93	0.67	0.72	-0.54	0.93	0.93	0.64	0.84	-0.21	0.73		0.89	0.65	0.97	0.75
Other Stockholder Equity	0.83	0.79	0.47	0.65	0.85	0.42	0.93	0.76	0.38	0.27	-0.95	0.79	0.69	0.58	-0.52	0.98	0.78	0.76	0.85	-0.36	0.79	0.89		0.43	0.85	0.82
Total Liab	0.72	0.69	-0.11	0.86	0.59	0.91	0.64	0.62	0.76	0.49	-0.61	0.81	0.57	0.82	-0.04	0.6	0.68	0.53	0.62	0.48	0.69	0.65	0.43		0.59	0.66
Net Invested Capital	0.99	0.6	-0.04	0.89	1.0	0.72	0.95	0.52	0.74	0.46	-0.83	0.83	0.49	0.66	-0.65	0.88	0.98	0.51	0.76	-0.35	0.6	0.97	0.85	0.59		0.62
Property Plant And Equipment Gross	0.67	1.0	0.54	0.64	0.62	0.52	0.82	0.99	0.37	0.46	-0.93	0.86	0.8	0.82	0.02	0.86	0.57	0.98	0.73	0.08	1.0	0.75	0.82	0.66	0.62

Click cells to compare fundamentals

Kymera Therapeutics Account Relationship Matchups

Kymera Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	116.7M	487.2M	605.9M	603.1M	575.8M	446.0M
Short Long Term Debt Total	21.2M	18.0M	18.0M	17.3M	84.7M	88.9M
Other Current Liab	4.6M	(67.4M)	(7.6M)	(8.3M)	34.4M	36.1M
Total Current Liabilities	34.6M	110.6M	101.0M	63.3M	85.7M	73.3M
Total Stockholder Equity	(74.4M)	283.9M	459.6M	490.2M	395.0M	278.6M
Other Liab	29.6M	77.9M	39.4M	28.2M	32.5M	38.6M
Net Tangible Assets	(74.4M)	283.9M	459.6M	490.2M	563.7M	591.9M
Property Plant And Equipment Net	22.1M	10.8M	11.9M	13.3M	101.1M	106.1M
Current Deferred Revenue	23.3M	170.4M	101.0M	63.3M	37.9M	73.0M
Net Debt	(54.8M)	(13.0M)	(30.0M)	(51.1M)	(25.3M)	(26.6M)
Retained Earnings	(76.5M)	(128.8M)	(229.0M)	(383.8M)	(530.8M)	(504.2M)
Accounts Payable	3.3M	4.4M	4.0M	4.3M	7.1M	4.6M
Cash	76.0M	31.0M	48.0M	68.4M	110.0M	68.7M
Non Current Assets Total	23.9M	184.8M	38.3M	43.6M	170.4M	179.0M
Non Currrent Assets Other	1.8M	11.5M	(98.8M)	(122.0M)	7.9M	8.3M
Other Assets	1.8M	1.6M	8.1M	9.1M	10.5M	11.0M
Cash And Short Term Investments	92.0M	458.7M	567.6M	559.5M	374.9M	383.9M
Net Receivables	287K	1.4M	135K	2.5M	18.8M	19.7M
Common Stock Shares Outstanding	44.5M	17.3M	48.0M	53.9M	58.4M	44.4M
Short Term Investments	15.9M	265.2M	394.4M	338.8M	264.9M	234.5M
Liabilities And Stockholders Equity	116.7M	487.2M	605.9M	603.1M	575.8M	446.0M
Non Current Liabilities Total	156.5M	92.7M	45.2M	49.7M	95.1M	68.4M
Capital Lease Obligations	21.2M	18.0M	18.0M	17.3M	84.7M	88.9M
Other Current Assets	888K	5.6M	8.9M	9.7M	11.7M	6.8M
Other Stockholder Equity	(107.0M)	(74.4M)	689.3M	878.9M	926.3M	972.6M
Total Liab	191.1M	203.3M	146.3M	113.0M	180.8M	167.4M
Net Invested Capital	(74.4M)	283.9M	459.6M	490.2M	395.0M	278.6M
Property Plant And Equipment Gross	22.1M	20.7M	25.2M	29.1M	111.5M	117.1M
Total Current Assets	92.8M	302.3M	567.6M	559.5M	405.3M	361.1M
Accumulated Other Comprehensive Income	6K	(128K)	(660K)	(4.9M)	(552K)	(579.6K)
Net Working Capital	58.3M	191.7M	358.7M	348.1M	319.6M	240.8M
Short Term Debt	3.4M	3.3M	3.6M	3.9M	6.3M	3.8M
Property Plant Equipment	22.1M	20.7M	11.9M	13.3M	15.3M	15.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Kymera Therapeutics is a strong investment it is important to analyze Kymera Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Kymera Therapeutics' future performance. For an informed investment choice regarding Kymera Stock, refer to the following important reports:

How To Invest In Kymera

Details

Is Kymera Stock a good investment?

Details

What is Kymera Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.

You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Kymera Stock analysis

When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Money Managers Screen money managers from public funds and ETFs managed around the world
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years

Is Kymera Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kymera Therapeutics. If investors know Kymera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kymera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.51)

Revenue Per Share

1.291

Quarterly Revenue Growth

0.087

Return On Assets

(0.15)

Return On Equity

(0.26)

The market value of Kymera Therapeutics is measured differently than its book value, which is the value of Kymera that is recorded on the company's balance sheet. Investors also form their own opinion of Kymera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Kymera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kymera Therapeutics' market value can be influenced by many factors that don't directly affect Kymera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kymera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kymera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kymera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kymera Begin Period Cash Flow vs Net Borrowings Analysis

Begin Period Cash Flow vs Net Borrowings

Begin Period Cash Flow vs Net Borrowings Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Net Borrowings

Kymera Therapeutics fundamental ratios Correlations

Kymera Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kymera Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Kymera Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Capital Lease Obligations
Total Stockholder Equity	+ 0.99	Total Assets
Net Invested Capital	+ 0.99	Total Assets

Other Assets	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Retained Earnings	- 0.94	Net Tangible Assets
Property Plant And Equipment Gross	- 0.93	Retained Earnings
Other Current Assets	- 0.91	Retained Earnings
Capital Lease Obligations	- 0.91	Retained Earnings